



Published in final edited form as:

Int J Biochem Cell Biol. 2017 November ; 92: 202–209. doi:10.1016/j.biocel.2017.10.006.

Selectivity of coronaridine congeners at nicotinic acetylcholine receptors and inhibitory activity on mouse medial habenula

Hugo R. Arias^{a,*}, Xiaotao Jin^b, Dominik Feuerbach^c, and Ryan M. Drenan^b

^aDepartment of Basic Sciences, California Northstate University College of Medicine, Elk Grove, CA, USA ^bDepartment of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA ^cNovartis Institutes for Biomedical Research, Basel, Switzerland

Abstract

The inhibitory activity of coronaridine congeners on human (h) $\alpha 4\beta 2$ and $\alpha 7$ nicotinic acetylcholine receptors (AChRs) is determined by Ca^{2+} influx assays, whereas their effects on neurons in the ventral inferior (VI) aspect of the mouse medial habenula (MHb) are determined by patch-clamp recordings. The Ca^{2+} influx results clearly establish that coronaridine congeners inhibit $\text{h}\alpha 3\beta 4$ AChRs with higher selectivity compared to $\text{h}\alpha 4\beta 2$ and $\text{h}\alpha 7$ subtypes, and with the following potency sequence, for $\text{h}\alpha 4\beta 2$: (\pm)-18-methoxycoronaridine [(\pm)-18-MC] > (+)-catharanthine > (\pm)-18-methylaminocoronaridine [(\pm)-18-MAC] \sim (\pm)-18-hydroxycoronaridine [(\pm)-18-HC]; and for $\text{h}\alpha 7$: (+)-catharanthine > (\pm)-18-MC > (\pm)-18-HC > (\pm)-18-MAC. Interestingly, the inhibitory potency of (+)-catharanthine ($27 \pm 4 \mu\text{M}$) and (\pm)-18-MC ($28 \pm 6 \mu\text{M}$) on MHb (VI) neurons was lower than that observed on $\text{h}\alpha 3\beta 4$ AChRs, suggesting that these compounds inhibit a variety of endogenous $\alpha 3\beta 4^*$ AChRs. In addition, the interaction of bupropion with (–)-ibogaine sites on $\text{h}\alpha 3\beta 4$ AChRs is tested by [^3H]ibogaine competition binding experiments. The results indicate that bupropion binds to ibogaine sites at desensitized $\text{h}\alpha 3\beta 4$ AChRs with 2-fold higher affinity than at resting receptors, suggesting that these compounds share the same binding sites. In conclusion, coronaridine congeners inhibit $\text{h}\alpha 3\beta 4$ AChRs with higher selectivity compared to other AChRs, by interacting with the bupropion (luminal) site. Coronaridine congeners also inhibit $\alpha 3\beta 4^*$ AChRs expressed in MHb (VI) neurons, supporting the notion that these receptors are important endogenous targets for their anti-addictive activities.

Keywords

Nicotinic acetylcholine receptor; Coronaridine congeners; 18-Methoxycoronaridine; (+)-Catharanthine; Medial habenula; Brain slices

1. Introduction

Pharmacologically, coronaridine congeners, including (–)-ibogaine and (\pm)-18-methoxycoronaridine [(\pm)-18-MC], behave as noncompetitive antagonists (NCAs) of several

*Corresponding author at: Department of Basic Sciences, California Northstate University College of Medicine, 9700 W. Taron Dr., Elk Grove, CA, USA. hugo.arias@cnsu.edu (H.R. Arias).

Author Manuscript

nicotinic acetylcholine receptors (AChRs) (Glick et al., 2002a; Pace et al., 2004; Arias et al., 2010a,b, 2011; Arias et al., 2015). From the therapeutic point of view, these compounds decrease drug self-administration in animals (Glick et al., 2000, 2002a,b; Maissoneuve and Glick, 2003) and interrupt drug dependence in humans (reviewed in Alper et al., 2008). In this regard, clinical trials are being conducted by the company Savant HWP to determine the potential therapeutic use and safety of 18-MC for nicotine and other drugs dependence.

Author Manuscript

An important distinction between the toxicity of (\pm)-18-MC and (-)-ibogaine is that the former compound has less side effects than the latter, which may produce hallucinogenic, cardiac (e.g., arrhythmia and bradycardia), and tremogenic effects, especially after prolonged use (Glick et al., 2000; Maissoneuve and Glick, 2003). The safer activity of (\pm)-18-MC compared to (-)-ibogaine has been ascribed to its higher receptor selectivity towards $\alpha 3\beta 4$ AChRs. However, the only experiment suggesting such receptor selectivity is based on a qualitative comparison between voltage-clamp recordings showing that 20 μ M (\pm)-18-MC inhibits only $\alpha 3\beta 4$ AChRs, whereas 20 μ M (-)-ibogaine inhibits both $\alpha 3\beta 4$ and $\alpha 4\beta 2$ subtypes (Glick et al., 2002a). To clarify this subject in a more thorough manner, the inhibitory potency (IC_{50}) of several coronaridine congeners, including (\pm)-18-MC, (+)-catharanthine, (\pm)-18-methylaminocoronaridine [(\pm)-18-MAC], and (\pm)-18-hydroxycoronaridine [(\pm)-18-HC] (see molecular structures in Fig. 1), is determined on $\alpha 4\beta 2$ and $\alpha 7$ AChRs and subsequently compared to that previously obtained on $\alpha 3\beta 4$ AChRs (Arias et al., 2015).

Author Manuscript

Previous studies support the hypothesis that the inhibition of $\alpha 3\beta 4^*$ AChRs expressed in the habenulo-interpeduncular cholinergic pathway modulates the dopaminergic brain reward circuitry located in the mesocorticolimbic system, and that this is the main mechanism underlying the anti-addictive properties of coronaridine congeners (McCallum et al., 2012; Glick et al., 2002a,b, 2011; Maissoneuve and Glick, 2003; reviewed in Ortells and Arias, 2010). Experiments showing that the local administration of 18-MC in the medial habenula (MHb) diminishes nicotine self-administration (Glick et al., 2011) support the above mentioned hypothesis. The same as results showing that lower doses of the antidepressant bupropion and 18-MC maintain the beneficial activity with less side effects (Maissoneuve and Glick, 2003), probably due to the demonstrated bupropion-induced $\alpha 3\beta 4$ AChR inhibition (reviewed in Arias et al., 2014). Nevertheless, no evidence of direct inhibition of habenular $\alpha 3\beta 4^*$ AChRs by 18-MC, nor a structural interaction between bupropion and (-)-ibogaine sites at $\alpha 3\beta 4$ AChRs, has been clearly demonstrated. In this regard, we sought to determine the activity of (\pm)-18-MC and (+)-catharanthine on MHb by brain slice electrophysiology recordings of ventral inferior (VI) MHb neurons, strongly expressing $\alpha 3\beta 4^*$ AChRs (Quick et al., 1999; Shih et al., 2014, 2015), as well as to determine the pharmacological interaction of bupropion with (-)-ibogaine sites at $\alpha 3\beta 4$ AChRs in different conformational states by radioligand competition binding experiments (Arias et al., 2015).

Author Manuscript

A better understanding of the functional interaction and selectivity of coronaridine congeners for neuronal AChRs, especially $\alpha 3\beta 4^*$ AChRs, expressed in heterologous cells and endogenous neurons is crucial to develop novel analogs for safer anti-addictive therapies.

2. Materials and methods

2.1. Materials

[³H]Ibogaine (23 Ci/mmol) and ibogaine hydrochloride were obtained through the National Institute on Drug Abuse (NIDA) (NIH, Baltimore, USA). [³H]Epibatidine (45.1 Ci/mmol) was purchased from PerkinElmer Life Sciences Products, Inc. (Boston, MA, USA). (±)-18-Methoxycoronaridine hydrochloride [(±)-18-MC] was purchased from Obiter Research, LLC (Champaign, IL, USA). (±)-18-Methylaminocoronaridine [(±)-18-MAC], (+)-catharanthine hydrochloride, and (±)-18-hydroxycoronaridine [(±)-18-HC] were a gift from Dr. Kuehne (University of Vermont, VT, USA). (±)-Epibatidine and QX-314 were obtained from Tocris Bioscience (Ellisville, MO, USA). Fluo-4 was obtained from Molecular Probes (Eugene, Oregon, USA). Euthasol (sodium pentobarbital, 100 mg/kg; sodium phenytoin, 12.82 mg/kg) was obtained from LeVet Pharma (Oudewater, Netherlands). Polyethylenimine, acetylcholine (ACh), (–)-nicotine hydrogen tartrate, bupropion hydrochloride, probenecid, and bovine serum albumin (BSA), were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Salts were of analytical grade.

2.2. Mice

An animal study protocol pertaining to this study (#IS00003604) was reviewed and approved by the Northwestern University Institutional Animal Care and Use Committee. Procedures also followed the guidelines for the care and use of animals provided by the National Institutes of Health (NIH) Office of Laboratory Animal Welfare. Mice were housed at 22 °C on a 12-h light/dark cycle with food and water ad libitum. Mice were weaned on postnatal day 21 and housed with same-sex littermates. Experiments were conducted on C57BL/6J mice obtained from Jackson Laboratories. All studies were restricted to male mice, age 8–24 weeks.

2.3. Ca²⁺ influx measurements in cells expressing hα4β2 or hα7 AChRs

Ca²⁺ influx measurements were performed on HEK293-hα4β2 and GH3-hα7 cells as previously described (Arias et al., 2010c, 2016). Briefly, 5 × 10⁴ cells per well were seeded 72 h prior to the experiment on black 96-well plates (Costar, New York, USA) and incubated at 37 °C in a humidified atmosphere (5% CO₂/95% air). Under these conditions, the majority of expressed hα4β2 AChRs have the (α4)₃(β2)₂ stoichiometry (see Arias et al., 2016, and references therein). 16–24 h before the experiment, the medium was changed to 1% BSA in HEPES-buffered salt solution (HBSS) (130 mM NaCl, 5.4 mM KCl, 2 mM CaCl₂, 0.8 mM MgSO₄, 0.9 mM NaH₂PO₄, 25 mM glucose, 20 mM HEPES, pH 7.4). On the day of the experiment, the medium was removed by flicking the plates and replaced with 100 μL HBSS/1% BSA containing 2 mM Fluo-4 and 2.5 mM probenecid. The cells were then incubated at 37 °C in a humidified atmosphere (5% CO₂/95% air) for 1 h.

To determine the antagonistic activity of each coronaridine congener (Fig. 1), plates were flicked to remove excess of Fluo-4, washed twice with HBSS/1% BSA, refilled with 100 μL of HBSS containing different concentrations of the ligand under study, and finally pre-incubated for 5 min. Plates were finally placed in the cell plate stage of the fluorescent imaging plate reader (FLIRP: Molecular Devices, Sunnyvale, CA, USA), and (±)-

epibatidine (0.1 μM for $\text{h}\alpha 4\beta 2$ AChRs or 1.0 μM for $\text{h}\alpha 7$ AChRs) added from the agonist plate to the cell plate using the 96-tip pipettor simultaneously to fluorescence recordings for a total length of 3 min. A baseline consisting of 5 measurements of 0.4 s each was recorded. (\pm)—The laser excitation and emission wavelengths are 488 and 510 nm, at 1 W, and a CCD camera opening of 0.4 s.

2.4. Brain slice preparation

Brain slices were prepared as previously described (Shih et al., 2014, 2015). Mice were anesthetized with Euthasol (sodium pentobarbital, 100 mg/kg; sodium phenytoin, 12.82 mg/kg) before transcardiac perfusion with oxygenated (95% O_2 /5% CO_2), 4 °C *N*-methyl-D-glucamine (NMDG)-based recovery solution that contains (in mM): 93 NMDG, 2.5 KCl, 1.2 NaH_2PO_4 , 30 NaHCO_3 , 20 HEPES, 25 glucose, 5 sodium ascorbate, 2 thiourea, 3 sodium pyruvate, 10 $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, and 0.5 $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$; 300–310 mOsm; pH 7.3–7.4). Brains were immediately dissected after the perfusion and held in oxygenated, 4 °C recovery solution for one minute before cutting a brain block containing the MHb and sectioning the brain with a vibratome (VT1200S; Leica). Coronal slices (250 μm) were sectioned through the medial habenula and transferred to oxygenated, 33 °C recovery solution for 12 min. Slices were then kept in holding solution (containing in mM: 92 NaCl, 2.5 KCl, 1.2 NaH_2PO_4 , 30 NaHCO_3 , 20 HEPES, 25 glucose, 5 sodium ascorbate, 2 thiourea, 3 sodium pyruvate, 2 $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, and 2 $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$; 300–310 mOsm; pH 7.3–7.4) for 60 min or more before recordings.

Brain slices were transferred to a recording chamber being continuously superfused at a rate of 1.5–2.0 mL/min with oxygenated 32 °C recording solution. The recording solution contained (in mM): 124 NaCl, 2.5 KCl, 1.2 NaH_2PO_4 , 24 NaHCO_3 , 12.5 glucose, 2 $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$, and 2 $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$; 300–310 mOsm; pH 7.3–7.4). Patch pipettes were pulled from borosilicate glass capillary tubes (1B150F-4; World Precision Instruments) using a programmable microelectrode puller (P-97; Sutter Instrument). Tip resistance ranged from 4.5 to 8.0 M Ω when filled with internal solution. The following internal solution was used (in mM): 135 potassium gluconate, 5 EGTA, 0.5 CaCl_2 , 2 MgCl_2 , 10 HEPES, 2 MgATP, and 0.1 GTP; pH adjusted to 7.25 with Tris base; osmolarity adjusted to 290 mOsm with sucrose. This internal solution also contained QX-314 (2 mM) for improved voltage control.

2.5. Patch clamp recording

Neurons within brain slices were visualized with infrared or visible differential interference contrast (DIC) optics. Neurons in the ventral inferior (VI) aspect of the MHb were targeted for recordings, as previously described (Shih et al., 2014, 2015). Electrophysiology experiments were conducted using a Scientifica SliceScope upright microscope. A computer running pCLAMP 10 software was used to acquire whole-cell recordings along with an Axopatch 200B amplifier and an A/D converter (Digidata 1440A). pClamp software and acquisition hardware were from Molecular Devices. Data were sampled at 10 kHz and low-pass filtered at 1 kHz. Immediately prior to gigaseal formation, the junction potential between the patch pipette and the superfusion medium was nulled. Series resistance was uncompensated.

To record physiological events following local application of drugs, a drug-filled pipette was moved to within 20–40 μm of the recorded neuron using a second micromanipulator. The drug (dissolved in recording solution) was dispensed onto the recorded neuron by using a Picopump (World Precision Instruments) at an ejection pressure of 12 psi for 250 ms. The ejection volume varied depending on the goal of the experiment. Atropine (1 μM) was present in the superfusion medium when using ACh application to prevent activation of muscarinic AChRs.

2.6. [^3H]ibogaine competition binding experiments using $\text{h}\alpha 3\beta 4$ AChRs-containing membranes

To determine whether the antidepressant bupropion binds to the coronaridine binding sites at $\text{h}\alpha 3\beta 4$ AChRs in different conformational states, [^3H]ibogaine competition binding experiments were performed using $\text{h}\alpha 3\beta 4$ AChR-containing membranes prepared from HEK293- $\text{h}\alpha 3\beta 4$ cells as previously described (Arias et al., 2010b). In this regard, $\text{h}\alpha 3\beta 4$ AChR membranes (1.0–1.5 mg/mL) were suspended in binding saline buffer (50 mM Tris–HCl, 120 mM NaCl, 5 mM KCl, 2 mM CaCl_2 , 1 mM MgCl_2 , pH 7.4) and pre-incubated with 16.6 nM [^3H]ibogaine in the absence (receptors are mainly in the resting state) and presence of 1 μM (–)-nicotine (receptors are mainly in the desensitized state) for 30 min at room temperature (RT). The total volume was divided into aliquots, and increasing concentrations of the ligand under study were added to each tube and incubated for 2 h at RT. The nonspecific binding was determined in the presence of 100 μM (–)-ibogaine.

AChR-bound [^3H]ibogaine was then separated from free ligand by a filtration assay using a 48-sample harvester system with GF/B Whatman filters (Brandel Inc., Gaithersburg, MD), previously soaked with 0.5% polyethylenimine for 30 min. The membrane-containing filters were transferred to scintillation vials with 3 mL of Bio-Safe II (Research Product International Corp, Mount Prospect, IL), and the radioactivity was determined using a Beckman 6500 scintillation counter (Beckman Coulter, Inc., Fullerton, CA).

2.7. Analysis methods

The concentration–response results from heterologous cells and MHb neurons, as well as from the radioligand competition binding experiments were curve-fitted by nonlinear least squares analysis using the Prism software (GraphPad Software, San Diego, CA), and the EC_{50} , IC_{50} , and n_{H} values for the studied ligands calculated. The obtained IC_{50} values for bupropion were transformed into an inhibition constant (K_i) values using the Cheng–Prusoff relationship (Cheng and Prusoff, 1973):

$$K_i = \text{IC}_{50} / \left\{ 1 + ([^3\text{H}]\text{ligand}) / K_d^{\text{ligand}} \right\} \quad (1)$$

where [^3H]ligand] is the initial concentration of [^3H]ibogaine or [^3H] epibatidine, and K_d^{ligand} is the dissociation constant for [^3H]ibogaine at the $\text{h}\alpha 3\beta 4$ AChR (0.46 μM ; Arias et al., 2010c).

To compare the affinity of bupropion at $\alpha 3\beta 4$ AChRs in different conformational states, the Student *t*-test (two-tail) was used.

3. Results

3.1. Inhibitory potency and AChR selectivity for coronaridine congeners

The activation potency of (\pm)-epibatidine on $\alpha 4\beta 2$ and $\alpha 7$ AChRs was first determined by assessing the fluorescence change in the respective $\alpha 4\beta 2$ - (Fig. 2) and $\alpha 7$ -expressing cells (Fig. 3) after (\pm)-epibatidine stimulation. The respective EC_{50} values for (\pm)-epibatidine (12 ± 5 and 26 ± 4 nM) are in the same range as previous determinations (Arias et al., 2010c, 2016).

The inhibitory activity of several coronaridine congeners (Fig. 1) was subsequently assessed by pre-incubating each compound with $\alpha 4\beta 2$ - (Fig. 2) and $\alpha 7$ -expressing cells (Fig. 3) for 5 min before (\pm)-epibatidine stimulation (0.1 and 1.0 μ M, respectively). Interestingly, each coronaridine congener inhibited (\pm)-epibatidine-induced $\alpha 4\beta 2$ and $\alpha 7$ AChR activity with IC_{50} values that depend on the ligand structure and AChR subtype (Table 1). For example, the ligand potency for the $\alpha 4\beta 2$ AChR follows the rank order: (\pm)-18-MC > (+)-catharanthine > (\pm)-18-MAC ~ (\pm)-18-HC, which is slightly different to that for $\alpha 7$ AChRs: (+)-catharanthine > (\pm)-18-MC > (\pm)-18-HC > (\pm)-18-MAC (Table 1).

Comparing the IC_{50} values obtained in the $\alpha 4\beta 2$ and $\alpha 7$ AChRs with that obtained in $\alpha 3\beta 4$ AChRs (Arias et al., 2015), the following receptor selectivity sequence was obtained: $\alpha 3\beta 4 > \alpha 4\beta 2 > \alpha 7$. Illustrating this selectivity, the values for (+)-catharanthine at $\alpha 3\beta 4$ AChRs are 18- and 32-fold higher than that for the respective $\alpha 4\beta 2$ and $\alpha 7$ AChRs (Table 1).

The results showing that the n_H values for the majority of the congeners [with exception of (\pm)-18-HC] are higher than unity (Table 1) indicate that the inhibitory process is mediated by a cooperative mechanism. A cooperative mechanism, in turn, suggests that there is potentially more than one binding site or several mechanisms of inhibition.

3.2. Inhibition of ACh-evoked currents from MHb (VI) neurons by coronaridine congeners

Patch-clamp recordings on MHb (VI) neurons showed that 100 μ M ACh puffs activated endogenous AChRs (see control traces in Figs. 4A and 5A). MHb (VI) neurons were identified primarily by their close proximity (< 50–70 μ m) to the 3rd ventricle within the ventral aspect of the MHb. They were secondarily distinguished from other nearby brain areas (e.g., thalamus and lateral habenula) via the presence of slow (1–8 Hz) tonic firing (Shih et al., 2014).

The observed inward currents elicited by ACh were reduced by superfusion of 180 μ M (\pm)-18-MC (Fig. 4A) or 180 μ M (+)-catharanthine (Fig. 5A), and drug washout for 13 and 10 min, respectively, resulted in complete recovery of the original response amplitude. The fact that the neuronal AChR activity was fully recovered after washing suggests that the recording remained stable and the reduction in current following coronaridine congener application was due neither to a large change in the seal quality nor input resistance but

rather to the intrinsic antagonistic activity of these ligands. A concentration-dependent inhibition was determined for 18-MC (Fig. 4B) and (+)-catharanthine (Fig. 5B) by using a wide range of concentrations (i.e., 0.07–180 μM). The single exponential fit gave r^2 (goodness-of-fit) values of 0.80 and 0.87, respectively. Although biphasic fitting slightly increased the r^2 values, suggesting two AChR populations, the accuracy of the IC_{50} values was lost. Thus, the inhibitory potency for (+)-catharanthine ($27 \pm 4 \mu\text{M}$) and 18-MC ($28 \pm 6 \mu\text{M}$) (Table 2) was calculated considering single exponential fit. The observed n_{H} values are lower than unity (Table 2), but still higher than 0.5, indicating that the inhibitory mechanism is mainly non-cooperative. These values only intend to make a comparison between both compounds, but due to different methodological approaches, they cannot be used to make a comparison with the n_{H} values obtained by Ca^{2+} influx.

3.3. Binding affinity of bupropion for the [^3H]ibogaine sites at $\alpha 3\beta 4$ AChRs in different conformational states

To determine whether bupropion binds to the [^3H]ibogaine binding sites at $\alpha 3\beta 4$ AChRs, the effect of this antidepressant on [^3H]ibogaine binding was determined on resting (i.e., in the absence of any agonist) and desensitized [i.e., in the presence of (–)-nicotine] $\alpha 3\beta 4$ AChRs (Fig. 6). The results indicated that the binding affinity of bupropion depends on the $\alpha 3\beta 4$ AChR conformational state. More specifically, bupropion interacts with the [^3H]ibogaine sites at desensitized $\alpha 3\beta 4$ AChRs with higher affinity ($K_i = 1.1 \pm 0.1 \mu\text{M}$) than that at resting receptors ($2.4 \pm 0.4 \mu\text{M}$) (Student t -test $p = 0.001$) (Table 3). The observed n_{H} values (close to unity) (Table 3) indicate that bupropion inhibits [^3H]ibogaine binding to $\alpha 3\beta 4$ AChRs in different conformational states by non-cooperative mechanisms. This suggest, in turn, that there is potentially only one binding site or several sites with similar binding affinity in the AChR.

4. Discussion

This work seek to demonstrate the AChR selectivity for coronaridine congeners, the inhibitory activity on native $\alpha 3\beta 4^*$ AChRs expressed in MHb (VI) neurons, and whether (–)-ibogaine, the archetype of these congeners (Arias et al., 2010b), and bupropion share the same binding site(s).

Combining the present Ca^{2+} influx results with previous data on $\alpha 3\beta 4$ AChRs (Arias et al., 2015), the following neuronal AChR selectivity was obtained for the studied coronaridine congeners: $\alpha 3\beta 4 > \alpha 4\beta 2 > \alpha 7$. The selectivity for $\alpha 1\beta 1\gamma\delta$ AChRs was in general between that for $\alpha 4\beta 2$ and $\alpha 7$ AChRs, except (\pm)-18-MAC and (\pm)-18-MC, which showed a higher and similar potency, respectively, compared to that for $\alpha 4\beta 2$ AChRs (Arias et al., 2011). Particularly, the selectivity of (\pm)-18-MC for $\alpha 3\beta 4$ AChRs is 4-fold compared to the $\alpha 4\beta 2$ AChR (Table 1), a value that agrees with that estimated by Glick's laboratory using electrophysiological recordings (Glick et al., 2002a). Interestingly, the selectivity of other coronaridine congeners for the $\alpha 3\beta 4$ AChR was even higher. For instance, the selectivity for (+)-catharanthine was 18-, 32-, and 29-fold higher than that for the respective $\alpha 4\beta 2$, $\alpha 7$ (this paper), and $\alpha 1\beta 1\gamma\delta$ AChRs (Arias et al., 2011), suggesting that this congener may produce less side effects compared to that for 18-MC, especially at

higher doses. This is the first time of a quantitative estimation of the receptor selectivity for coronaridine congeners, an important pharmacological feature related to their anti-addictive properties (Glick et al., 2002a).

An important feature of (–)-ibogaine and (±)-18-MC is that their anti-addictive effects last for prolonged time (reviewed in Glick et al., 2000). In this regard, 18-MC is rapidly metabolized (i.e., half-life ~100 min) to 18-HC (Zhang et al., 2002; Maissonneuve and Glick, 2003), which also has higher selectivity for $\alpha_3\beta_4$ AChRs (this paper), suggesting a potential role in the behavioral effects mediated by 18-MC. However, only small amounts of this metabolite were found in tissues, indicating that it may account for only a minimal activity (Maissonneuve and Glick, 2003). Alternatively, the observed deposition of 18-MC in fat tissues (e.g., brain) may account for its prolonged duration of action (Maissonneuve and Glick, 2003).

The results indicating that other NCAs with anti-addictive properties such as bupropion (i.e., antidepressant that decreases withdrawal and craving effects during smoking cessation; reviewed in Arias et al., 2014) and mecamylamine (e.g., decreases alcohol and nicotine rewarding effects in men; Chi and de Wit, 2003) show higher selectivity for $\alpha_3\beta_4$ AChRs (Arias et al., 2014; Papke et al., 2001) are in agreement with the observed synergistic effects between each one of these drugs and 18-MC (Glick et al., 2002a,b; Maissonneuve and Glick, 2003). More specifically, inactive doses of bupropion (or mecamylamine) and 18-MC produce the same anti-addictive activity as 18-MC at higher doses. These correlations support the idea that this receptor subtype is an important target for the development of pharmacotherapies for drug addiction. The observed anti-addictive activity of AT-1001, a competitive antagonist with high affinity and selectivity for $\alpha_3\beta_4$ AChRs (Toll et al., 2012), also supports this concept.

The Ca^{2+} influx results also showed the following inhibitory potency (in μM) sequence for the $\alpha_4\beta_2$ AChR: (±)-18-MC (6.3 ± 1.3) > (+)-catharanthine (12.6 ± 1.8) > (±)-18-MAC (20.7 ± 3.0) ~ (±)-18-HC (24.8 ± 1.2), which is similar as that for $\alpha_3\beta_4$ AChRs (Arias et al., 2015), but slightly different to that for α_7 AChRs, and very different to that for muscle-type AChRs (Arias et al., 2011). This altered sequence could be ascribed to subtle structural differences among AChR subtypes. For example, (–)-18-MC (Arias et al., 2015) and (–)-ibogaine (Arias et al., 2010b) interact with the $\alpha_3\beta_4$ AChR at a luminal site formed between the phenylalanine/valine (position 13') and serine (position 6') rings. Fig. 7 illustrates the location of the ibogaine binding site in the lumen of the $\alpha_3\beta_4$ AChR ion channel (modified from Arias et al., 2010b). In particular, the aromatic rings of each ligand form π - π interactions with β_4 -Phe255 residues at position 13' (Arias et al., 2010b; Arias et al., 2015). Since a valine ring (position 13') is instead found at the $\alpha_4\beta_2$ and α_7 AChRs (Arias et al., 2016; Vázquez-Gómez et al., 2014; reviewed in Arias et al., 2014), the Phe residues are not present, decreasing ligand (i.e., π - π) interaction, and thus inhibitory activity, as observed in our results.

Our competition binding results indicated that bupropion inhibits [^3H]ibogaine binding to desensitized $\alpha_3\beta_4$ AChRs with 2-fold higher affinity than that for resting AChRs. The observed affinity difference and concentration range is similar to that observed for (–)-

ibogaine itself (1.05 and 0.37 μM , respectively; Arias et al., 2010b). Since the [^3H]ibogaine binding competition is mediated by a non-cooperative mechanism (i.e., $n_{\text{H}} \sim 1$), bupropion is probably interacting with only one [^3H]ibogaine site or few sites with similar affinities at $\text{h}\alpha 3\beta 4$ AChRs. Previous molecular docking results suggested that coronaridine congeners interact with a luminal site located between the phenylalanine/valine and serine rings of the $\text{h}\alpha 3\beta 4$ AChR ion channel (Arias et al., 2010b; Arias et al., 2015), overlapping the bupropion site (Arias et al., submitted manuscript) as well as the site for other structurally-different antidepressants, including imipramine (Arias et al., 2010d) and fluoxetine (Arias et al., 2010c). Fig. 7 illustrates the $\text{h}\alpha 3\beta 4$ AChR model with overlapping binding sites for (-)-ibogaine (cyan) (Arias et al., 2010b) and (-)-bupropion (magenta) (Arias et al., submitted manuscript).

The patch-clamp results showed, for the first time, that coronaridine congeners inhibit ACh-evoked currents from MHb (VI) neurons. Interestingly, the neuronal AChR activity was fully recovered after washing, suggesting that the ligands interact with portions of the AChR that are in contact with an aqueous environment such as the ion channel. The majority (~75%) of the current response at MHb (VI) neurons has been ascribed to $\alpha 3\beta 4^*$ AChRs (Quick et al., 1999). Although MHb neurons also express $\alpha 4$ -containing AChRs, including $\alpha 4\beta 4$, $\alpha 4\beta 2$, and $\alpha 4\beta 3\beta 2$ subtypes (Grady et al., 2009; Scholze et al., 2012), they are preferably concentrated in MHb (VL) neurons (Shih et al., 2014). Based on our results using heterologous cells, we expected a potent blockade of $\alpha 3\beta 4^*$ AChRs by (+)-catharanthine and (\pm)-18-MC. Interestingly, the observed IC_{50} values for (+)-catharanthine ($27 \pm 4 \mu\text{M}$) and (\pm)-18-MC ($28 \pm 6 \mu\text{M}$) are much higher than those observed at $\text{h}\alpha 3\beta 4$ AChRs (0.68 ± 0.10 and $1.47 \pm 0.21 \mu\text{M}$, respectively) (Arias et al., 2015). This is not surprising, as drug potency may be diminished in a tissue slice. Nevertheless, it is possible to suggest that the observed potency differences could be due to the expression of a variety of $\alpha 3\beta 4^*$ AChRs in MHb neurons whereas HEK293- $\text{h}\alpha 3\beta 4$ cells express only $\text{h}\alpha 3\beta 4$ AChRs. Supporting this assumption, there is evidence of MHb neurons expressing $\alpha 3$ -containing AChRs, including $\alpha 3\beta 4$, $\alpha 3\beta 2$, $\alpha 3\beta 4\beta 2$, $\alpha 3\beta 4\beta 3$, $\alpha 3\alpha 4\beta 4$, $\alpha 3\alpha 6\beta 4$, and $\alpha 3\alpha 5\beta 4\beta 2$ subtypes (Quick et al., 1999; Grady et al., 2009; Scholze et al., 2012; Shih et al., 2014, 2015). Based on this variety of receptors, it is plausible that some of them, including their respective stoichiometric variants such as $(\alpha 3)_2(\beta 4)_3$ and $(\alpha 3)_3(\beta 4)_2$, may have lower sensitivity to coronaridine congeners, as observed with functionally-different ligands (Ochoa et al., 2016; Shih et al., 2015; Krashia et al., 2010). In this regard, future work will determine the activity of coronaridine congeners on specific $\alpha 3\beta 4$ -containing AChRs and stoichiometries using heterologous cells and knockout mice.

Our findings clearly demonstrate that coronaridine congeners present higher selectivity for $\text{h}\alpha 3\beta 4$ AChRs compared to other AChR subtypes. These compounds block the $\text{h}\alpha 3\beta 4$ AChR in a noncompetitive fashion by interacting with the bupropion (luminal) site. The results showing that coronaridine congeners inhibit MHb (VI) neurons support that concept that native $\alpha 3\beta 4^*$ AChRs are targets for the pharmacological and anti-addictive activity of these compounds.

Acknowledgments

This work was supported by grants from NIH (DA040626) (to R.M.D.), and California Northstate University College of Medicine (to H.R.A.). The authors thank to National Institute on Drug Addiction (NIDA, NIH, Bethesda, Maryland, USA) for the gift of ibogaine, to Dr. Kuehne (University of Vermont, VT, USA) for the gift of coronaridine congeners, to Dr. Targowska-Duda (Medical University of Lublin, Poland) for providing the $\alpha_3\beta_4$ AChR model with the overlapping sites for ibogaine and bupropion, and to Dr. Scholze (University of Vienna, Austria) for her fruitful comments.

Abbreviations

AChR	nicotinic acetylcholine receptor
ACh	acetylcholine
NCA	noncompetitive antagonist
RT	room temperature
MHb	medial habenula
VI	ventral inferior
K_i	inhibition constant
K_d	dissociation constant
IC₅₀	ligand concentration that produces 50% inhibition of binding (or of agonist activation)
EC₅₀	agonist concentration that produces 50% receptor activation
n_H	Hill coefficient
r²	goodness-of-fit for the linear regression
DMEM	Dulbecco's Modified Eagle Medium
BSA	bovine serum albumin
HBSS	HEPES-buffered salt solution
(-)-ibogaine	12-methoxyibogamine
(±)-18-MC	(±)-18-methoxycoronaridine
(±)-18-MAC	(±)-18-methylaminocoronaridine
(±)-18-HC	(±)-18-hydroxycoronaridine
(+)-catharanthine	(+)-3,4-didehydrocoronaridine

References

- Alper KR, Lots of HS, Kaplan CD. The ibogaine medical subculture. *J Ethnopharmacol.* 2008; 115:9–24. [PubMed: 18029124]
- Arias HR, Rosenberg A, Feuerbach D, Targowska-Duda KM, Maciejewski R, Moaddel R, Glick SD, Wainer IW. Interaction of 18-methoxycoronaridine with nicotinic acetylcholine receptors in different conformational states. *Biochem Biophys Acta.* 2010a; 1798:1153–1163. [PubMed: 20303928]
- Arias HR, Rosenberg A, Targowska-Duda KM, Feuerbach D, Yuan XJ, Jozwiak K, Moaddel R, Wainer IW. Interaction of ibogaine with human $\alpha 3\beta 4$ -nicotinic acetylcholine receptors in different conformational states. *Int J Biochem Cell Biol.* 2010b; 42:1525–1535. [PubMed: 20684041]
- Arias HR, Feuerbach D, Targowska-Duda KM, Russell M, Jozwiak K. Interaction of selective serotonin reuptake inhibitors with neuronal nicotinic acetylcholine receptors. *Biochemistry.* 2010c; 49:5734–5742. [PubMed: 20527991]
- Arias HR, Targowska-Duda KM, Feuerbach D, Sullivan CJ, Maciejewski R, Jozwiak K. Different interaction between tricyclic antidepressants and mecamylamine with the human $\alpha 3\beta 4$ nicotinic acetylcholine receptor ion channel. *Neurochem Int.* 2010d; 56:642–649. [PubMed: 20117161]
- Arias HR, Feuerbach D, Targowska-Duda KM, Jozwiak K. Structure-activity relationship of ibogaine analogs interacting with nicotinic acetylcholine receptors in different conformational states. *Int J Biochem Cell Biol.* 2011; 43:1330–1339. [PubMed: 21642011]
- Arias HR, Biała G, Kruk-Słomka M, Targowska-Duda KM. Interaction of nicotinic receptors with bupropion: structural functional, and pre-clinical perspectives. *Recept Clin Invest.* 2014; 1:30–45.
- Arias HR, Feuerbach D, Targowska-Duda KM, Jozwiak K. Coronaridine congeners inhibit human $\alpha 3\beta 4$ nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites. *Int J Biochem Cell Biol.* 2015; 65:81–90. [PubMed: 26022277]
- Arias HR, Feuerbach D, Ortells MO. Bupropion and its photoreactive analog (\pm)-SADU-3-72 interact with luminal and non-luminal sites at human $\alpha 4\beta 2$ nicotinic acetylcholine receptors. *Neurochem Int.* 2016; 100:67–77. [PubMed: 27612850]
- Cheng Y, Prusoff WH. Relationship between the inhibition constant (K_i) and the concentration of inhibitor which causes 50 percent inhibition (IC_{50}) of an enzymatic reaction. *Biochem Pharmacol.* 1973; 22:3099–3108. [PubMed: 4202581]
- Chi H, de Wit H. Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers. *Alcohol Clin Exp Res.* 2003; 27:780–787. [PubMed: 12766622]
- Glick SD, Maisonneuve IM, Szumlinski KK. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. *Ann NY Acad Sci.* 2000; 914:369–386. [PubMed: 11085336]
- Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW. Antagonism of $\alpha 3\beta 4$ nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. *Eur J Pharmacol.* 2002a; 438:99–105. [PubMed: 11906717]
- Glick SD, Maisonneuve IM, Kitchen BA. Modulation of nicotine self-administration in rats by combination therapy with agents blocking $\alpha 3\beta 4$ nicotinic receptors. *Eur J Pharmacol.* 2002b; 448:185–191. [PubMed: 12144940]
- Glick SD, Sell EM, McCallum SE, Maisonneuve IM. Brain regions mediating $\alpha 3\beta 4$ nicotinic antagonist effects of 18-MC on nicotine self-administration. *Eur J Pharmacol.* 2011; 669:71–75. [PubMed: 21871879]
- Grady SR, Moretti M, Zoli M, Marks MJ, Zanardi A, Pucci L, Clementi F, Gotti C. Rodent habenulo-interpeduncular pathway expresses a large variety of uncommon nAChR subtypes, but only the $\alpha 3\beta 4^*$ and $\alpha 3\beta 3\beta 4^*$ subtypes mediate acetylcholine release. *J Neurosci.* 2009; 29:2272–2282. [PubMed: 19228980]
- Krashia P, Moroni M, Broadbent S, Hofmann G, Kracun S, Beato M, Groot-Kormelink PJ, Sivilotti LG. Human $\alpha 3\beta 4$ neuronal nicotinic receptors show different stoichiometry if they are expressed in *Xenopus oocytes* or mammalian HEK293 cells. *PLoS One.* 2010; 5:e13611. [PubMed: 21049012]

- Maisonneuve IM, Glick SD. Anti-addictive actions of an iboga alkaloid congener: a novel mechanism for a novel treatment. *Pharmacol Biochem Behav.* 2003; 75:607–618. [PubMed: 12895678]
- McCallum SE, Cowe MA, Lewis SW, Glick SD. $\alpha 3\beta 4$ nicotinic acetylcholine receptors in the medial habenula modulate the mesolimbic dopaminergic response to acute nicotine *in vivo*. *Neuropharmacology.* 2012; 3:434–440.
- Ochoa V, George AA, Nishi R, Whiteaker P. The protoxin LYPD6B modulates heteromeric $\alpha 3\beta 4$ -containing nicotinic acetylcholine receptors but not $\alpha 7$ homomers. *FASEB J.* 2016; 30:1109–1119. [PubMed: 26586467]
- Ortells MO, Arias HR. Neuronal networks of nicotine addiction. *Int J Biochem Cell Biol.* 2010; 42:1931–1935. [PubMed: 20833261]
- Pace CJ, Glick SD, Maisonneuve IM, He LW, Jokiel PA, Kuehne ME, Fleck MW. Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. *Eur J Pharmacol.* 2004; 492:159–167. [PubMed: 15178360]
- Papke RL, Sanberg PR, Shytle RD. Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes. *J Pharmacol Exp Ther.* 2001; 297:646–656. [PubMed: 11303054]
- Quick MW, Ceballos RM, Kasten M, McIntosh JM, Lester RA. $\alpha 3\beta 4$ subunit-containing nicotinic receptors dominate function in rat medial habenula neurons. *Neuropharmacology.* 1999; 38:769–783. [PubMed: 10465681]
- Scholze P, Koth G, Ort-Urtreger A, Huck S. Subunit composition of $\alpha 5$ -containing nicotinic receptors in the rodent habenula. *J Neurochem.* 2012; 12:551–560.
- Shih PY, Engle SE, Oh G, Deshpande P, Puskar NL, Lester HA, Drenan RM. Differential expression and function of nicotinic acetylcholine receptors in subdivisions of medial habenula. *J Neurosci.* 2014; 34:9789–9802. [PubMed: 25031416]
- Shih PY, McIntosh JM, Drenan RM. Nicotine dependence reveals distinct responses from neurons and their resident nicotinic receptors in medial habenula. *Mol Pharmacol.* 2015; 88:1035–1044. [PubMed: 26429939]
- Toll L, Zaveri NT, Polgar WE, Jiang F, Khroyan LV, Zhou W, Xie X, Stauber GB, Costello MR, Leslie FM. AT-1001: A high affinity and selective $\alpha 3\beta 4$ nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. *Neuropsychopharmacology.* 2012; 37:1367–1376. [PubMed: 22278092]
- Vázquez-Gómez E, Arias HR, Feuerbach D, Miranda-Morales M, Mihailescu S, Targowska-Duda KM, Jozwiak K, García-Colunga J. Bupropion-induced inhibition of $\alpha 7$ nicotinic acetylcholine receptors expressed in heterologous cells and neurons from dorsal raphe nucleus and hippocampus. *Eur J Pharmacol.* 2014; 740:103–111. [PubMed: 25016090]
- Zhang W, Ramamoorthy Y, Tyndale RF, Glick SD, Maisonneuve IM, Kuehne ME, Sellers EM. Metabolism of 18-methoxycoronaridine an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. *Drug Metab Dispos.* 2002; 30:663–669. [PubMed: 12019193]




Fig. 1. Molecular structure of coronaridine congeners in the protonated state, including (-)-18-MC [(-)-18-methoxycoronaridine], (-)-18-HC [(-)-18-hydroxycoronaridine], (-)-18-MAC [(-)-18-methylaminocoronaridine], and (+)-catharanthine [(+)-3,4-didehydrocoronaridine].




Fig. 2.

Effect of coronaridine congeners on (±)-epibatidine-induced Ca^{2+} influx in HEK293-h α 4 β 2 cells. Increased concentrations of (±)-epibatidine (■) activated h α 4 β 2 AChRs with potency $\text{EC}_{50} = 12 \pm 5$ nM ($n = 25$). Subsequently, cells were pre-treated (5 min) with several concentrations of (+)-catharanthine (▲), (±)-18-MC (○), (±)-18-MAC (□), and (±)-18-HC (●), followed by addition of 0.1 μM (±)-epibatidine. Response was normalized to the maximal (±)-epibatidine response which was set as 100%. The plots are representative of four determinations, where the error bars are the S.D. The calculated IC_{50} and n_{H} values are summarized in Table 1.




Fig. 3. Effect of coronaridine congeners on (±)-epibatidine-induced Ca^{2+} influx in GH3- $\alpha 7$ cells. Increased concentrations of (±)-epibatidine (■) activated $\alpha 7$ AChRs with potency $\text{EC}_{50} = 26 \pm 4$ nM ($n = 25$). Subsequently, cells were pre-treated (5 min) with several concentrations of (+)-catharanthine (▲), (±)-18-MC (○), (±)-18-MAC (□), and (±)-18-HC (●), followed by addition of $1.0 \mu\text{M}$ (±)-epibatidine. Response was normalized to the maximal (±)-epibatidine response which was set as 100%. The plots are representative of four determinations, where the error bars are the S.D. The calculated IC_{50} and n_{H} values are summarized in Table 1.




Fig. 4. Inhibitory potency of (±)-18-MC on ACh-evoked currents from MHb (VI) neurons. (A) ACh puffer (100 μM)-evoked currents from MHb (VI) neurons are decreased by 180 μM (±)-18-MC. The puffer was performed for 250 ms at a pressure of 12 psi. After washing (13 min), the peak amplitude reached the same levels as that observed in control neurons, indicating a reversible inhibition. (B) Concentration-response relationship for the inhibitory activity of (±)-18-MC on ACh-evoked currents from MHb (VI) neurons. Response was normalized to the maximal ACh response which was set as 100%. The plot ($r^2 = 0.80$) is representative of 5–7 determinations, where the error bars are the S.D. The calculated IC_{50} and n_H values are summarized in Table 2.




Fig. 5. Inhibitory potency of (+)-catharanthine on ACh-evoked currents from MHb (VI) neurons. (A) ACh puffer (100 μM)-evoked currents from MHb (VI) neurons are decreased by 180 μM (+)-catharanthine. The puffer was performed for 250 ms at a pressure of 12 psi. After washing (10 min), the peak amplitude reached the same levels as that observed in control neurons, indicating a reversible inhibition. (B) Concentration-response relationship for the inhibitory activity of (+)-catharanthine on MHb (VI) neurons. Response was normalized to the maximal ACh response which was set as 100%. The plot ($r^2 = 0.87$) is representative of 4–7 determinations, where the error bars are the S.D. The calculated IC_{50} and n_{H} values are summarized in Table 2.




Fig. 6. Bupropion-induced inhibition of [^3H]ibogaine binding to $\text{h}\alpha 3\beta 4$ AChRs in the resting (\square) and desensitized (\circ) states, respectively. $\text{h}\alpha 3\beta 4$ AChR membranes (1.5 mg/mL) were pre-incubated (30 min) with 16.6 nM [^3H]ibogaine in the absence (receptors are mainly in the resting state) and presence of 1 μM (–)-nicotine (receptors are mainly in the desensitized state), and then equilibrated with increasing concentrations of bupropion. Nonspecific binding was determined at 100 μM (–)-ibogaine. The plots are combinations of two experiments, each performed in triplicate, where the error bars are the S.D. The IC_{50} and n_{H} values were obtained by nonlinear least-squares fit of the plots ($r^2 = 0.95$ for both). The K_{i} values, calculated using eq. 1 and summarized in Table 3, indicated that bupropion binds to desensitized $\text{h}\alpha 3\beta 4$ AChRs with higher affinity than that at resting receptors (Student t -test $p = 0.001$).




Fig. 7. Model of the h α 3 β 4 AChR transmembrane domain showing the ion channel lumen (modified from Arias et al., 2010b). (-)-Ibogaine (cyan) interacts with a luminal site formed between the phenylalanine/valine (position 13') and serine (position 6') rings (Arias et al., 2010b), which overlaps the site for (-)-bupropion (magenta) (Arias et al., submitted manuscript). The AChR and ligands are depicted by its solvent accessible surface.

Table 1

Inhibitory potency (IC₅₀) of coronaridine congeners at hα₄β₂ and ha7 AChRs determined by Ca²⁺ influx assays.

Congener	hα ₄ β ₂		ha7		hα ₄ β ₂ /hα ₃ β ₄ ^c (x-fold)	ha7/hα ₃ β ₄ ^c (x-fold)
	IC ₅₀ , μM ^a	n _H ^b	IC ₅₀ , μM ^a	n _H ^b		
(±)-18-MC	6.3 ± 1.3	1.85 ± 0.17	34.7 ± 5.0	2.21 ± 0.50	4.3	23.6
(+)-Catharanthine	12.6 ± 1.8	1.48 ± 0.25	21.8 ± 2.5	1.43 ± 0.20	18.5	32.0
(±)-18-MAC	20.7 ± 3.0	1.40 ± 0.14	No effect	–	7.9	–
(±)-18-HC	24.8 ± 1.2	1.27 ± 0.06	73.3 ± 10.8	1.64 ± 0.20	8.8	26.1

^aThe Ca²⁺ influx results for hα₄β₂ and ha7 AChRs were obtained from Figures 2 and 3, respectively.

^bHill coefficient.

^cThe calculated ratios were obtained using the data on hα₃β₄ AChRs previously published (Arias et al., 2015).

Table 2

Inhibitory potency (IC₅₀) of (+)-catharanthine and (±)-18-MC at ACh-evoked currents on HMb (VI) neurons determined by patch-clamp recording.

Coronaridine Congener	IC ₅₀ , μM ^a	n _H ^b
(±)-18-MC	28 ± 6	0.65 ± 0.10
(+)-Catharanthine	27 ± 4	0.67 ± 0.08

^aThe IC₅₀ values for (±)-18-MC and (+)-catharanthine were obtained from Figs. 4 and 5, respectively.

^bHill coefficient.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

Binding affinity of bupropion for the [³H]ibogaine sites at $\alpha_3\beta_4$ AChRs in the resting and desensitized states.

Resting state [no agonist]		Desensitized state [in the presence of (-)-nicotine]	
K_i , μM^a	n_H^b	K_i , μM^a	n_H^b
2.4 ± 0.4	0.72 ± 0.05	1.1 ± 0.1	0.75 ± 0.08

^aThe IC₅₀ values obtained from Fig. 6 were transformed into K_i values using Eq. (1).

^bHill coefficient.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript